<DOC>
	<DOCNO>NCT00530842</DOCNO>
	<brief_summary>The primary objective study demonstrate treatment free combination tiotropium salmeterol provide superior improvement static lung volume exercise tolerance compare fix combination fluticasone salmeterol patient COPD . The secondary objective include assessment safety .</brief_summary>
	<brief_title>Effect Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol Static Lung Volumes Exercise Endurance COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>1 . The patient sign Informed Consent Form accordance GCP local legislative requirement prior participation trial , i.e. , prior pretrial washout restrict medication . 2 . The patient clinical diagnosis chronic obstructive pulmonary disease ( COPD ) . 3 . The patient relatively stable , moderate severe airway obstruction . 4 . The patient prebronchodilator force expiratory volume first second ( FEV1 ) less equal 65 % predict normal determined Visit 1 use follow predicted equation ( R941408 ) : 1 . Males Forced expiratory volume first second ( FEV1 ) predict [ Litres ( L ) ] = 4.30 x Height [ metres ] minus 0.029 x Age [ year ] minus 2.49 2 . Females Forced expiratory volume first second ( FEV1 ) predict [ Litres ( L ) ] = 3.95 x Height [ metres ] minus 0.025 x Age [ year ] minus 2.60 Thoracic Gas Volume ( Functional residual volume ) ( ( TGV ) ( FRC ) ) big 120 % predict normal visit 1 ( historical data older 6 month ) 3 . Males Thoracic Gas Volume ( Functional residual volume ) ( ( TGV ( FRC ) ) pred . [ Litres ( L ) ] = 2.34 x Height [ metres ] + 0.009 x Age [ year ] minus 1.09 4 . Females Thoracic Gas Volume ( Functional residual volume ) ( ( TGV ( FRC ) ) pred . [ Litres ( L ) ] = 2.24 x Height [ metres ] + 0.001 x Age [ year ] minus 1.00 5 . The patient least 40 year less equal 75 year old . 6 . The patient cigarette smoke history least 10 packyears . A packyear defined equivalent smoke one pack cigarettes per day year . 7 . The patient able perform specify procedure able maintain necessary record study period require protocol . 8 . The patient able inhale trial medication HandiHaler device . 9 . The patient able inhale trial medication Diskus/Accuhaler device . 1. significant disease chronic obstructive pulmonary disease ( COPD ) . ( review contraindication exercise test ) , 2. recent history myocardial infarction within one year . 3. recent history heart failure , pulmonary oedema , patient cardiac arrhythmia contraindication exercise describe CTProtocol within last 3 . 4. daytime supplemental oxygen . 5. diagnosis know active tuberculosis . 6. history cancer within last 5 year . 7. history lifethreatening pulmonary obstruction , history cystic fibrosis bronchiectasis . 8. thoracotomy pulmonary resection . 9. upper respiratory tract infection exacerbation chronic obstructive pulmonary disease ( COPD ) 10. know hypersensitivity anticholinergic drug , ÃŸadrenergic corticosteroid , lactose component inhalation capsule delivery system . 11. know symptomatic prostatic hypertrophy bladder neck obstruction . 12. known moderate severe renal insufficiency . 13. know narrowangle glaucoma . 14. know untreated hypokalemia . 15. know untreated thyrotoxicosis . 16. history asthma , allergic rhinitis atopy , total blood eosinophil count large 600/mm3 . 17. treatment cromolyn sodium nedocromil sodium 18. treatment antihistamine antileukotrienes . 19. treatment tiotropium 1 month Visit 1 . 20. treatment oral corticosteroid medication . 21 . Pregnant nursing woman woman childbearing potential use medically approve mean contraception 22. history active alcohol drug abuse . 23. investigational drug within 1 month 10 half live 24. limitation exercise performance result factor fatigue exertional dyspnoea . 25. participation rehabilitation program chronic obstructive pulmonary disease ( COPD ) . 26. treatment monoamine oxidase inhibitor inhibitor tricyclic antidepressant . 27. participation another study . 28. eight puff salbutamol/day runin period</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>